MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Clovis Oncology, Inc. (NASDAQ: CLVS)
Finance & Acquisition: Clovis Oncology
Parents
Clovis Oncology, Inc. (NASDAQ: CLVS)
Children
2008: Clovis raised a $146 million Series A round in 2008 from Domain Associates (20.2% pre-IPO stake), New Enterprise Associates (20.2%), Versant Ventures (14.4%), Aberdare Ventures (8.7%), Abingworth (8.7%) and ProQuest Investments.
2010: Avila struck a $209 million partnership deal with Clovis Oncology (2010)
2011: Acquirer, developer and commercializer of anti-cancer agents, has filed for a $149.5 million IPO (2011)
2015: UPDATED: Clovis Oncology shares crash after lung cancer response rate deteriorates
2016: Anticipated FDA rejection of rociletinib forces Clovis to cut headcount 35% by year end - Clovis Oncology (NASDAQ:CLVS)
2022: Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Clovis Oncology Inc Stock Quote: CLVS Stock News, Quotes, Analysis
Clovis Oncology_www.crunchbase.com
Clovis Oncology, Inc. (CLVS) Analyst Research
It plans to trade on the Nasdaq under ticker symbol CLVS, with JP Morgan and Credit Suisse serving as co-lead underwriters.
Jumps
*Key People: Clovis Oncology
Organization & Developments: Clovis Oncology